Cortisol and the polycystic ovary syndrome

References

• The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004).
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D et al.; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91(11), 4237–4245 (2006).
   PubMed Web of Science ®Google Scholar
• Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N. Engl. J. Med. 358(1), 47–54 (2008).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N. Engl. J. Med. 352(12), 1223–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Pasquali R. Obesity and androgens: facts and perspectives. Fertil. Steril. 85(5), 1319–1340 (2006).
   PubMed Web of Science ®Google Scholar
• Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J. Clin. Endocrinol. Metab. 81(8), 2854–2864 (1996).
   PubMed Web of Science ®Google Scholar
• Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol. Metab. Clin. North Am. 28(2), 265–293 (1999).
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Azziz R. The adrenal and polycystic ovary syndrome. Rev. Endocr. Metab. Disord. 8(4), 331–342 (2007).
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Woods KS, Stanczyk F, Bartolucci A, Azziz R. Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89(11), 5558–5562 (2004).
   PubMed Web of Science ®Google Scholar
• Lightman SL. The neuroendocrinology of stress: a never ending story. J. Neuroendocrinol. 20(6), 880–884 (2008).
   PubMed Web of Science ®Google Scholar
• Herman JP, Figueiredo H, Mueller NK et al. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo–pituitary–adrenocortical responsiveness. Front. Neuroendocrinol. 24(3), 151–180 (2003).
   PubMed Web of Science ®Google Scholar
• Viau V. Functional cross-talk between the hypothalamic–pituitary–gonadal and – drenal axes. J. Neuroendocrinol. 14(6), 506–513 (2002).
   PubMed Web of Science ®Google Scholar
• Williamson M, Bingham B, Viau V. Central organization of androgen-sensitive pathways to the hypothalamic–pituitary–adrenal axis: implications for individual differences in responses to homeostatic threat and predisposition to disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(8), 1239–1248 (2005).
   PubMed Web of Science ®Google Scholar
• Lanzone A, Petraglia F, Fulghesu AM, Ciampelli M, Caruso A, Mancuso S. Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome. Fertil. Steril. 63(6), 1195–1199 (1995).
   PubMed Web of Science ®Google Scholar
• Lanzone A, Fulghesu AM, Guido M, Cucinelli F, Caruso A, Mancuso S. Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome. Fertil. Steril. 67(1), 34–39 (1997).
   PubMed Web of Science ®Google Scholar
• Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic–pituitary–adrenal axis. J. Clin. Endocrinol. Metab. 83(7), 2317–2323 (1998).
   PubMed Web of Science ®Google Scholar
• Wu XK, Zhou SY, Sallinen K, Pöllänen P, Erkkola R. Ovarian-adrenal cross-talk in polycystic ovary syndrome: evidence from wedge resection. Eur. J. Endocrinol. 143(3), 383–388 (2000).
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Uemura T, Ishikawa M, Yokoi N, Hirahara F. Classification of polycystic ovary syndrome into three types according to response to human corticotropin-releasing hormone. Fertil. Steril. 72(1), 15–20 (1999).
   PubMed Web of Science ®Google Scholar
• Fulghesu AM, Ciampelli M, Guido M et al. Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease. Metab. Clin. Exp. 47(2), 158–162 (1998).
   PubMed Web of Science ®Google Scholar
• Lanzone A, Guido M, Ciampelli M et al. Evidence of a disturbance of the hypothalamic–pituitary–adrenal axis in polycystic ovary syndrome: effect of naloxone. Clin. Endocrinol. 45(1), 73–77 (1996).
   PubMed Web of Science ®Google Scholar
• Gennarelli G, Holte J, Stridsberg M et al. Response of the pituitary–adrenal axis to hypoglycemic stress in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 84(1), 76–81 (1999).
   PubMed Web of Science ®Google Scholar
• Gurusinghe D, Gill S, Almario RU et al. In polycystic ovary syndrome, adrenal steroids are regulated differently in the morning versus in response to nutrient intake. Fertil. Steril. 93(4), 1192–1199 (2010).
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Roelfsema F, Iranmanesh A, Carroll BJ, Keenan DM, Pincus SM. Basal, pulsatile, entropic (patterned), and spiky (staccato-like) properties of ACTH secretion: impact of age, gender, and body mass index. J. Clin. Endocrinol. Metab. 94(10), 4045–4052 (2009).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Vicennati V, Gambineri A, Pagotto U. Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity. Int. J. Obes. 32(12), 1764–1779 (2008).
   PubMed Web of Science ®Google Scholar
• Chalew S, Nagel H, Shore S. The hypothalamic–pituitary–adrenal axis in obesity. Obes. Res. 3(4), 371–382 (1995).
   PubMedGoogle Scholar
• Pasquali R, Biscotti D, Spinucci G et al. Pulsatile secretion of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution. Clin. Endocrinol. 48(5), 603–612 (1998).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Cantobelli S, Casimirri F et al. The hypothalamic–pituitary–adrenal axis in obese women with different patterns of body fat distribution. J. Clin. Endocrinol. Metab. 77(2), 341–346 (1993).
   PubMed Web of Science ®Google Scholar
• Duclos M, Corcuff JB, Etcheverry N, Rashedi M, Tabarin A, Roger P. Abdominal obesity increases overnight cortisol excretion. J. Endocrinol. Invest. 22(6), 465–471 (1999).
   PubMed Web of Science ®Google Scholar
• Epel EE, Moyer AE, Martin CD et al. Stress-induced cortisol, mood, and fat distribution in men. Obes. Res. 7(1), 9–15 (1999).
   PubMedGoogle Scholar
• Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamic–pituitary–adrenal axis activity in obesity and the metabolic syndrome. Ann. NY Acad. Sci. 1083, 111–128 (2006).
   PubMed Web of Science ®Google Scholar
• Vicennati V, Pasquali R. Abnormalities of the hypothalamic–pituitary–adrenal axis in women with the abdominal obesity and relationship with insulin resistance: evidence for a central and peripheral alteration. J. Clin. Endocrinol. Metab. 24, 416–422 (2000).
   Google Scholar
• Bertagna X, Coste J, Raux-Demay MC, Letrait M, Strauch G. The combined corticotropin-releasing hormone/lysine vasopressin test discloses a corticotroph phenotype. J. Clin. Endocrinol. Metab. 79(2), 390–394 (1994).
   PubMed Web of Science ®Google Scholar
• Mårin P, Darin N, Amemiya T, Andersson B, Jern S, Björntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metab. Clin. Exp. 41(8), 882–886 (1992).
   PubMed Web of Science ®Google Scholar
• Ljung T, Andersson B, Bengtsson BA, Björntorp P, Mårin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes. Res. 4(3), 277–282 (1996).
   PubMedGoogle Scholar
• Pasquali R, Ambrosi B, Armanini D et al.; Study Group on Obesity of the Italian Society of Endocrinology. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J. Clin. Endocrinol. Metab. 87(1), 166–175 (2002).
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Kok P, Pereira AM, Pijl H. Cortisol production rate is similarly elevated in obese women with or without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95(7), 3318–3324 (2010).
   PubMed Web of Science ®Google Scholar
• Dunkelman SS, Fairhurst B, Plager J, Waterhouse C. Cortisol metabolism in obesity. J. Clin. Endocrinol. Metab. 24, 832–841 (1964).
   PubMed Web of Science ®Google Scholar
• Strain GW, Zumoff B, Strain JJ, Levin J, Fukushima DK. Cortisol production in obesity. Metab. Clin. Exp. 29(10), 980–985 (1980).
   PubMed Web of Science ®Google Scholar
• Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J. Clin. Endocrinol. Metab. 84(3), 1022–1027 (1999).
   PubMed Web of Science ®Google Scholar
• Andrew R, Phillips DI, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J. Clin. Endocrinol. Metab. 83(5), 1806–1809 (1998).
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Kahn SE, Samuels MH, Brandon D, Loriaux DL, Brunzell JD. Enhanced cortisol production rates, free cortisol, and 11b-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. Am. J. Physiol. Endocrinol. Metab. 296(2), E351–E357 (2009).
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Kok P, Frolich M, Pereira AM, Pijl H. Disordered and increased adrenocorticotropin secretion with diminished adrenocorticotropin potency in obese in premenopausal women. J. Clin. Endocrinol. Metab. 94(8), 2991–2997 (2009).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Casimirri F, De Iasio R et al. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J. Clin. Endocrinol. Metab. 80(2), 654–658 (1995).
   PubMed Web of Science ®Google Scholar
• Poretsky L, Piper B. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet. Gynecol. 84(4), 613–621 (1994).
   PubMed Web of Science ®Google Scholar
• Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J. Clin. Invest. 83(1), 23–29 (1989).
   PubMed Web of Science ®Google Scholar
• Nestler JE, Clore JN, Strauss JF 3rd, Blackard WG. The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans. J. Clin. Endocrinol. Metab. 64(1), 180–184 (1987).
   PubMed Web of Science ®Google Scholar
• Stuart CA, Prince MJ, Peters EJ, Meyer WJ 3rd. Hyperinsulinemia and hyperandrogenemia: in vivo androgen response to insulin infusion. Obstet. Gynecol. 69(6), 921–925 (1987).
   PubMed Web of Science ®Google Scholar
• Lawson MA, Jain S, Sun S, Patel K, Malcolm PJ, Chang RJ. Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women. J. Clin. Endocrinol. Metab. 93(6), 2089–2096 (2008).
   PubMed Web of Science ®Google Scholar
• Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 20(4), 535–582 (1999).
   PubMed Web of Science ®Google Scholar
• Tosi F, Negri C, Perrone F et al. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 97(5), 1712–1719 (2012).
   PubMed Web of Science ®Google Scholar
• Hines GA, Smith ER, Azziz R. Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: preliminary studies. Fertil. Steril. 76(4), 730–735 (2001).
   PubMed Web of Science ®Google Scholar
• Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 123(2), 733–739 (1988).
   PubMed Web of Science ®Google Scholar
• Rosenfield RL, Barnes RB, Cara JF, Lucky AW. Dysregulation of cytochrome P450c 17 α as the cause of polycystic ovarian syndrome. Fertil. Steril. 53(5), 785–791 (1990).
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C et al. Insulin infusion amplifies 17 α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J. Clin. Endocrinol. Metab. 81(3), 881–886 (1996).
   PubMed Web of Science ®Google Scholar
• Tosi F, Negri C, Brun E et al. Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. Eur. J. Endocrinol. 164(2), 197–203 (2011).
   PubMed Web of Science ®Google Scholar
• Romualdi D, Giuliani M, Draisci G et al. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil. Steril. 88(1), 131–138 (2007).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Hermann AP, Hagen C et al. A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome. Fertil. Steril. 91(3), 842–850 (2009).
   PubMed Web of Science ®Google Scholar
• Vrbíková J, Hill M, Stárka L et al. The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur. J. Endocrinol. 144(6), 619–628 (2001).
   PubMed Web of Science ®Google Scholar
• Unlühizarci K, Kelestimur F, Sahin Y, Bayram F. The treatment of insulin resistance does not improve adrenal cytochrome P450c17α enzyme dysregulation in polycystic ovary syndrome. Eur. J. Endocrinol. 140(1), 56–61 (1999).
   PubMed Web of Science ®Google Scholar
• Benson S, Arck PC, Tan S et al. Disturbed stress responses in women with polycystic ovary syndrome. Psychoneuroendocrinology 34(5), 727–735 (2009).
   PubMed Web of Science ®Google Scholar
• Hill AJ, Williams J. Psychological health in a non-clinical sample of obese women. Int. J. Obes. Relat. Metab. Disord. 22(6), 578–583 (1998).
   PubMed Web of Science ®Google Scholar
• Johnson F, Wardle J. Dietary restraint, body dissatisfaction, and psychological distress: a prospective analysis. J. Abnorm. Psychol. 114(1), 119–125 (2005).
   PubMed Web of Science ®Google Scholar
• Vicennati V, Pasqui F, Cavazza C, Pagotto U, Pasquali R. Stress-related development of obesity and cortisol in women. Obesity (Silver Spring). 17(9), 1678–1683 (2009).
   PubMed Web of Science ®Google Scholar
• Vicennati V, Pasqui F, Cavazza C et al. Cortisol, energy intake, and food frequency in overweight/obese women. Nutrition 27(6), 677–680 (2011).
   PubMed Web of Science ®Google Scholar
• Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H, Akana SF. Minireview: glucocorticoids – food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 145(6), 2633–2638 (2004).
   PubMed Web of Science ®Google Scholar
• Leal AM, Moreira AC. Food and the circadian activity of the hypothalamic–pituitary–adrenal axis. Braz. J. Med. Biol. Res. 30(12), 1391–1405 (1997).
   PubMed Web of Science ®Google Scholar
• Ishizuka B, Quigley ME, Yen SS. Pituitary hormone release in response to food ingestion: evidence for neuroendocrine signals from gut to brain. J. Clin. Endocrinol. Metab. 57(6), 1111–1116 (1983).
   PubMed Web of Science ®Google Scholar
• Follenius M, Brandenberger G, Hietter B. Diurnal cortisol peaks and their relationships to meals. J. Clin. Endocrinol. Metab. 55(4), 757–761 (1982).
   PubMed Web of Science ®Google Scholar
• Slag MF, Ahmad M, Gannon MC, Nuttall FQ. Meal stimulation of cortisol secretion: a protein induced effect. Metab. Clin. Exp. 30(11), 1104–1108 (1981).
   PubMed Web of Science ®Google Scholar
• Gibson EL, Checkley S, Papadopoulos A, Poon L, Daley S, Wardle J. Increased salivary cortisol reliably induced by a protein-rich midday meal. Psychosom. Med. 61(2), 214–224 (1999).
   PubMed Web of Science ®Google Scholar
• Korbonits M, Trainer PJ, Little JA et al. Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary–adrenal activity. Clin. Endocrinol. 46(6), 751–757 (1997).
   PubMed Web of Science ®Google Scholar
• Vicennati V, Ceroni L, Gagliardi L, Gambineri A, Pasquali R. Comment: response of the hypothalamic-pituitary-adrenocortical axis to high-protein/fat and high-carbohydrate meals in women with different obesity phenotypes. J. Clin. Endocrinol. Metab. 87(8), 3984–3988 (2002).
   PubMed Web of Science ®Google Scholar
• de Niet JE, de Koning CM, Pastoor H et al. Psychological well-being and sexarche in women with polycystic ovary syndrome. Hum. Reprod. 25(6), 1497–1503 (2010).
   PubMed Web of Science ®Google Scholar
• Sundararaman PG, Shweta, Sridhar GR. Psychosocial aspects of women with polycystic ovary syndrome from south India. J. Assoc. Physicians India 56, 945–948 (2008).
   PubMedGoogle Scholar
• Eggers S, Kirchengast S. The polycystic ovary syndrome – a medical condition but also an important psychosocial problem. Coll. Antropol. 25(2), 673–685 (2001).
   PubMedGoogle Scholar
• Barry JA, Hardiman PJ, Saxby BK, Kuczmierczyk A. Testosterone and mood dysfunction in women with polycystic ovarian syndrome compared to subfertile controls. J. Psychosom. Obstet. Gynaecol. 32(2), 104–111 (2011).
   PubMed Web of Science ®Google Scholar
• Brady C, Mousa SS, Mousa SA. Polycystic ovary syndrome and its impact on women’s quality of life: more than just an endocrine disorder. Drug. Healthc. Patient Saf. 1, 9–15 (2009).
   PubMedGoogle Scholar
• Lim SS, Norman RJ, Clifton PM, Noakes M. Hyperandrogenemia, psychological distress, and food cravings in young women. Physiol. Behav. 98(3), 276–280 (2009).
   PubMed Web of Science ®Google Scholar
• Dallman MF. Stress-induced obesity and the emotional nervous system. Trends Endocrinol. Metab. 21(3), 159–165 (2010).
   PubMed Web of Science ®Google Scholar
• Altieri P, Cavazza C, Pasqui F, Morselli AM, Gambineri A, Pasquali R. Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome. Clin. Endocrinol. doi:10.1111/j.1365-2265.2012.04355.x (2012) (Epub ahead of print).
   Google Scholar
• Mormede P, Foury A, Barat P et al. Molecular genetics of hypothalamic–pituitary–adrenal axis activity and function. Ann. NY Acad. Sci. 1220, 127–136 (2011).
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat. Rev. Endocrinol. 7(4), 219–231 (2011).
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Guo X, Yildiz BO, Stanczyk FZ, Azziz R. Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters. Am. J. Obstet. Gynecol. 196(4), 398.e1–e5; discussion 398.e5 (2007).
   Web of Science ®Google Scholar
• Glintborg D, Hermann AP, Brusgaard K, Hangaard J, Hagen C, Andersen M. Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J. Clin. Endocrinol. Metab. 90(3), 1347–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Valkenburg O, Uitterlinden AG, Themmen AP et al. Genetic polymorphisms of the glucocorticoid receptor may affect the phenotype of women with anovulatory polycystic ovary syndrome. Hum. Reprod. 26(10), 2902–2911 (2011).
   PubMed Web of Science ®Google Scholar
• Gagliardi L, Ho JT, Torpy DJ. Corticosteroid-binding globulin: the clinical significance of altered levels and heritable mutations. Mol. Cell. Endocrinol. 316(1), 24–34 (2010).
   PubMed Web of Science ®Google Scholar
• Seckl JR, Walker BR. Minireview: 11b-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology 142(4), 1371–1376 (2001).
   PubMed Web of Science ®Google Scholar
• Stewart PM, Krozowski ZS. 11 b-Hydroxysteroid dehydrogenase. Vitam. Horm. 57, 249–324 (1999).
   PubMed Web of Science ®Google Scholar
• Andrew R, Smith K, Jones GC, Walker BR. Distinguishing the activities of 11b-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. J. Clin. Endocrinol. Metab. 87(1), 277–285 (2002).
   PubMed Web of Science ®Google Scholar
• Basu R, Singh RJ, Basu A et al. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-b hydroxysteroid dehydrogenase (11b-hsd) type 1 pathway. Diabetes 53(8), 2051–2059 (2004).
   PubMed Web of Science ®Google Scholar
• Monder C, White PC. 11 b-hydroxysteroid dehydrogenase. Vitam. Horm. 47, 187–271 (1993).
   PubMed Web of Science ®Google Scholar
• Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294(5549), 2166–2170 (2001).
   PubMed Web of Science ®Google Scholar
• Morton NM, Holmes MC, Fiévet C et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11b-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276(44), 41293–41300 (2001).
   PubMed Web of Science ®Google Scholar
• Rebuffé-Scrive M. Neuroregulation of adipose tissue: molecular and hormonal mechanisms. Int. J. Obes. 15(Suppl. 2), 83–86 (1991).
   PubMedGoogle Scholar
• Paterson JM, Morton NM, Fievet C et al. Metabolic syndrome without obesity: hepatic overexpression of 11b-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl Acad. Sci. USA 101(18), 7088–7093 (2004).
   PubMed Web of Science ®Google Scholar
• Hermanowski-Vosatka A, Balkovec JM, Cheng K et al. 11b-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202(4), 517–527 (2005).
   PubMed Web of Science ®Google Scholar
• Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11b-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54(3), 872–879 (2005).
   PubMed Web of Science ®Google Scholar
• Basu R, Singh RJ, Basu A et al. Obesity and Type 2 diabetes do not alter splanchnic cortisol production in humans. J. Clin. Endocrinol. Metab. 90(7), 3919–3926 (2005).
   PubMed Web of Science ®Google Scholar
• Wake DJ, Rask E, Livingstone DE, Söderberg S, Olsson T, Walker BR. Local and systemic impact of transcriptional up-regulation of 11b-hydroxysteroid dehydrogenase Type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88(8), 3983–3988 (2003).
   PubMed Web of Science ®Google Scholar
• Gambineri A, Repaci A, Patton L et al. Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. Nutr. Metab. Cardiovasc. Dis. 19(11), 797–804 (2009).
   PubMed Web of Science ®Google Scholar
• Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 b-hydroxysteroid dehydrogenase. N. Engl. J. Med. 330(7), 460–465 (1994).
   PubMed Web of Science ®Google Scholar
• Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5α-reduction but not the elevated adrenal steroid production rates. J. Clin. Endocrinol. Metab. 88(12), 5907–5913 (2003).
   PubMed Web of Science ®Google Scholar
• Gambineri A, Forlani G, Munarini A et al. Increased clearance of cortisol by 5b-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J. Endocrinol. Invest. 32(3), 210–218 (2009).
   PubMed Web of Science ®Google Scholar
• Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 α-reductase activity in polycystic ovary syndrome. Lancet 335(8687), 431–433 (1990).
   PubMed Web of Science ®Google Scholar
• Chin D, Shackleton C, Prasad VK et al. Increased 5α-reductase and normal 11b-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome. J. Pediatr. Endocrinol. Metab. 13(3), 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Gambineri A, Tomassoni F, Munarini A et al. A combination of polymorphisms in HSD11B1 associates with in vivo 11{b}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur. J. Endocrinol. 165(2), 283–292 (2011).
   PubMed Web of Science ®Google Scholar
• Svendsen PF, Madsbad S, Nilas L, Paulsen SK, Pedersen SB. Expression of 11b-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome. Int. J. Obes. 33(11), 1249–1256 (2009).
   Web of Science ®Google Scholar
• Tomlinson JW, Walker EA, Bujalska IJ et al. 11b-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25(5), 831–866 (2004).
   PubMed Web of Science ®Google Scholar
• Wake DJ, Homer NZ, Andrew R, Walker BR. Acute in vivo regulation of 11b-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans. J. Clin. Endocrinol. Metab. 91(11), 4682–4688 (2006).
   PubMed Web of Science ®Google Scholar
• Draper N, Echwald SM, Lavery GG et al. Association studies between microsatellite markers within the gene encoding human 11b-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. J. Clin. Endocrinol. Metab. 87(11), 4984–4990 (2002).
   PubMed Web of Science ®Google Scholar
• Nair S, Lee YH, Lindsay RS et al. 11b-Hydroxysteroid dehydrogenase type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 47(6), 1088–1095 (2004).
   PubMed Web of Science ®Google Scholar
• Franks PW, Knowler WC, Nair S et al. Interaction between an 11bHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians. Hypertension 44(5), 681–688 (2004).
   PubMed Web of Science ®Google Scholar
• Draper N, Walker EA, Bujalska IJ et al. Mutations in the genes encoding 11b-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat. Genet. 34(4), 434–439 (2003).
   PubMed Web of Science ®Google Scholar
• Gambineri A, Vicennati V, Genghini S et al. Genetic variation in 11b-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91(6), 2295–2302 (2006).
   PubMed Web of Science ®Google Scholar